Cargando…
Severe CIDP-MGUS responsive to Rituximab
Chronic inflammatory demyelinating polyneuropathy (CIDP) is a relatively rare disease with progressive limb weakness and sensory loss. A few patients show a severely progressing course without major response to intravenous immunoglobulin or plasma exchange therapy. CIDP-MGUS (monoclonal gammopathy o...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306592/ https://www.ncbi.nlm.nih.gov/pubmed/32596526 http://dx.doi.org/10.1016/j.heliyon.2020.e04230 |
_version_ | 1783548686329970688 |
---|---|
author | Posa, Andreas Emmer, Alexander Kornhuber, Malte |
author_facet | Posa, Andreas Emmer, Alexander Kornhuber, Malte |
author_sort | Posa, Andreas |
collection | PubMed |
description | Chronic inflammatory demyelinating polyneuropathy (CIDP) is a relatively rare disease with progressive limb weakness and sensory loss. A few patients show a severely progressing course without major response to intravenous immunoglobulin or plasma exchange therapy. CIDP-MGUS (monoclonal gammopathy of undetermined significance) is a seldom CIDP variant that has been rarely addressed in therapeutic studies. In the presented CIDP-MGUS case, B cell depletion with rituximab had a favourable effect on the disease course, clinically and in nerve conduction studies. |
format | Online Article Text |
id | pubmed-7306592 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-73065922020-06-25 Severe CIDP-MGUS responsive to Rituximab Posa, Andreas Emmer, Alexander Kornhuber, Malte Heliyon Article Chronic inflammatory demyelinating polyneuropathy (CIDP) is a relatively rare disease with progressive limb weakness and sensory loss. A few patients show a severely progressing course without major response to intravenous immunoglobulin or plasma exchange therapy. CIDP-MGUS (monoclonal gammopathy of undetermined significance) is a seldom CIDP variant that has been rarely addressed in therapeutic studies. In the presented CIDP-MGUS case, B cell depletion with rituximab had a favourable effect on the disease course, clinically and in nerve conduction studies. Elsevier 2020-06-18 /pmc/articles/PMC7306592/ /pubmed/32596526 http://dx.doi.org/10.1016/j.heliyon.2020.e04230 Text en © 2020 The Authors. Published by Elsevier Ltd. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Posa, Andreas Emmer, Alexander Kornhuber, Malte Severe CIDP-MGUS responsive to Rituximab |
title | Severe CIDP-MGUS responsive to Rituximab |
title_full | Severe CIDP-MGUS responsive to Rituximab |
title_fullStr | Severe CIDP-MGUS responsive to Rituximab |
title_full_unstemmed | Severe CIDP-MGUS responsive to Rituximab |
title_short | Severe CIDP-MGUS responsive to Rituximab |
title_sort | severe cidp-mgus responsive to rituximab |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7306592/ https://www.ncbi.nlm.nih.gov/pubmed/32596526 http://dx.doi.org/10.1016/j.heliyon.2020.e04230 |
work_keys_str_mv | AT posaandreas severecidpmgusresponsivetorituximab AT emmeralexander severecidpmgusresponsivetorituximab AT kornhubermalte severecidpmgusresponsivetorituximab |